Gerresheimer’s share price increased by approximately 22% over the past month. The stock gained 24% over the last three months, reversing a substantial decline recorded over the past year.
Investors are reassessing the company’s valuation following its acquisition of Bormioli Pharma. While the recent momentum is significant, no specific market analysis has identified a single cause for the sudden rebound.
Current analysis suggests Gerresheimer trades at a 13% discount to its intrinsic value. However, the stock price currently sits 10% above average analyst price targets. These conflicting metrics present a mixed valuation signal for potential investors weighing recent performance against long-term trends.